isr - ISR STOCK NEWS

PharmaLogic Holdings Corp., a contract development organization, has signed a Master Services Agreement with Viewpoint Molecular Targeting, Inc. (NYSE AMERICAN: CATX) for the development of theranostics VMT-01 and VMT-α-NET. These radiopharmaceuticals are aimed at diagnosing and treating metastatic melanoma and neuroendocrine tumors. PharmaLogic will supply doses for Perspective's clinical trials, leveraging its expertise in radiopharmaceuticals. This collaboration is expected to enhance the precision of cancer treatments, with clinical trials set to begin enrollment soon, and preliminary results anticipated later this year.

Perspective Therapeutics has received a $1 million grant from the UK’s Medical Research Council (MRC) to support preclinical studies of [212Pb]VMT-α-NET for treating neuroendocrine tumors (NETs). The funding will be directed to Dr. Samantha Terry at King's College London, focusing on the interactions between radiation and cells to enhance cancer therapy. The research emphasizes using alpha-particle emissions for targeted cancer treatment, which aims to improve patient outcomes. Perspective Therapeutics continues to advance its pipeline with therapies for various cancers, including melanoma and NETs.

Perspective Therapeutics announced positive results from the first patient dosed with 212Pb-VMT-α-NET in India under compassionate use. The treatment showed favorable responses, as monitored by the somatostatin imaging agent 68Ga-DOTANOC, after a single low dose.

Dr. Vikas Prasad presented these findings at the 2023 PET Radiotracer Workshops. Encouraging responses indicate that VMT-α-NET is a promising candidate for treating neuroendocrine tumors (NETs). No adverse reactions were reported, and patients remained stable post-administration. This signifies potential advancements in precision oncology.

Perspective Therapeutics, Inc. (formerly Isoray, Inc.) reported a 35% decline in revenue to $1.84 million for the quarter ending December 31, 2022, primarily due to a 50% decrease in prostate brachytherapy sales. Operating expenses rose to $3.70 million, with notable increases attributed to legal and merger-related costs. The net loss widened to $2.90 million, compared to $1.60 million the previous year. Despite challenges, CEO Thijs Spoor emphasized advancements in targeted alpha therapy for cancers like melanoma. The company completed its merger with Viewpoint Molecular Targeting and plans to change its ticker to CATX on February 21, 2023.

Isoray, Inc. (NYSE AMERICAN: ISR) is rebranding to Perspective Therapeutics, Inc. following its merger with Viewpoint Molecular Targeting, Inc. The change includes a new tagline, "Treating cancers from the inside out," and a new website. The ticker symbol will transition to CATX on February 21, 2023. Perspective Therapeutics focuses on innovation in cancer treatments utilizing advanced radiopharmaceuticals, including Cesium-131 brachytherapy seeds and a lead-212 isotope. Their therapies are entering Phase 1/2a trials for metastatic melanoma and neuroendocrine tumors, showcasing a commitment to precision oncology.

Isoray, Inc. (AMEX: ISR) has successfully merged with Viewpoint Molecular Targeting, Inc. as of February 3, 2023, enhancing its capabilities in cancer treatment through radiopharmaceuticals. The merger fosters a unified mission to develop precision oncology treatments utilizing Cesium-131 and proprietary targeting peptides. Each Viewpoint share was converted into 3.1642 shares of Isoray, totaling about 49% of the combined company’s shares. Thijs Spoor of Viewpoint takes on the role of CEO with Lori Woods as Chairperson. This strategic alignment aims to create patient-focused therapies and increase stockholder value.

Isoray, Inc. (NYSE AMERICAN: ISR) announced that its stockholders approved Proposal One during the adjourned Fiscal 2023 Annual Meeting on January 27, 2023. This proposal allows an increase in the company’s authorized shares of common stock to 750 million. A total of 71,844,322 shares, representing 50.55% of outstanding shares, voted in favor. This approval paves the way for a merger with Viewpoint Molecular Targeting, Inc., which Isoray expects to complete soon. The company specializes in targeted internal radiation treatments for cancer and is the sole producer of Cesium-131 brachytherapy seeds.

Isoray, Inc. (NYSE AMERICAN: ISR) announced the adjournment of its Annual Meeting of Stockholders to January 27, 2023, to allow more time for stockholders to vote on Proposal 1, which seeks to increase authorized shares for a merger with Viewpoint Molecular Targeting. Proposal 1 needs majority approval and currently has 67.5 million votes in favor, with 3.6 million more needed. The Board and proxy firms recommend support for the proposal, which is seen as a transformational opportunity for the company and its shareholders.

Isoray, Inc. (NYSE AMERICAN: ISR) announced the adjournment of its December 13, 2022 Annual Meeting to January 12, 2023. This decision aims to provide additional time for stockholders to vote on Proposal 1, which is crucial to amend the Company's Certificate of Incorporation and approve the merger with Viewpoint Molecular Targeting, Inc. Stockholders currently in favor total 52,741,902 shares, needing 18,314,481 more for approval. The management believes the merger offers a transformational opportunity by combining existing business with innovative product pipelines.